| Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. | |
| | |
MedLine Citation:
|
PMID: 21036792 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
OBJECTIVE: To determine the efficacy of tenofovir disoproxil fumarate (TDF) in adults with chronic hepatitis B virus (HBV) infection who had previously failed lamivudine (LAM) and had significant viral replication (HBV DNA >10⁵ copies/ml if HBeAg positive, > 10⁴ copies/ml if HBeAg negative) despite at least 24 weeks of treatment with adefovir dipivoxil (ADV). DESIGN: A prospective open-label study of TDF 300 mg daily. Patients receiving combination ADV/LAM prior to baseline were switched to TDF/LAM. SETTING: Multiple tertiary referral centres. METHODS: Sixty patients were enrolled. The median age was 48.5 years (range 21e80), 46 (77%) were male and 40 (67%) were HBeAg positive. Thirty-eight patients (63%) were switched from ADV to TDF, the remainder from ADV/LAM to TDF/LAM. At baseline, substitutions conferring resistance to LAM or ADV were present in 20 patients (33%) and 17 patients (28%), respectively. The median baseline viral load was 5.33 log₁₀ IU/ml (range 2.81-8.04). Patients initially treated with TDF monotherapy with persistent viral replication at or after 24 weeks were switched to TDF/LAM. The main outcome measures were change in HBV viral load from baseline and percentage of patients achieving an undetectable viral load (<15 IU/ml). RESULTS: Results are reported at 96 weeks of treatment. One patient discontinued TDF at 10 days due to rash. The time-weighted change in viral load from baseline to week 12 was -2.19 log10 IU/ml overall. The median change in HBV DNA from baseline to weeks 12, 24, 48 and 96 was -2.86, -3.23, -3.75 and -4.03 log₁₀ IU/ml, respectively. At 48 and 96 weeks, 27/59 (46%) and 38/59 (64%) patients achieved a HBV DNA <15 IU/ml. The response was independent of baseline LAM therapy or mutations conferring ADV resistance. CONCLUSIONS: In heavily pretreated patients with a high rate of genotypic resistance, TDF retains significant activity against HBV although this appears diminished in comparison with studies of naïve patients. |
| | |
Authors:
|
S J Patterson; J George; S I Strasser; A U Lee; W Sievert; A J Nicoll; P V Desmond; S K Roberts; S Locarnini; S Bowden; P W Angus |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2010-10-29 |
Journal Detail:
|
Title: Gut Volume: 60 ISSN: 1468-3288 ISO Abbreviation: Gut Publication Date: 2011 Feb |
Date Detail:
|
Created Date: 2011-01-05 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 2985108R Medline TA: Gut Country: England |
Other Details:
|
Languages: eng Pagination: 247-54 Citation Subset: AIM; IM |
Affiliation:
|
Liver Transplant Unit, Austin Health, Studley Road, Heidelberg, VIC 3084, Australia. scott.patterson@austin.org.au |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
| Comments/Corrections | |
Comment In:
|
Gut. 2011 Feb;60(2):148-50
[PMID:
21205876
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Cardiovascular mortality during heat and cold events: determinants of regional vulnerability in Taiw...
Next Document: Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and inter...